Surgery Partners (NASDAQ:SGRY) Stock Rating Cut to “Hold” at UBS Group

Surgery Partners (NASDAQ:SGRY – Get Free Report) was downgraded by investment analysts at UBS Group from a “buy” rating to a “hold” rating in a report issued on Wednesday, MarketBeat reports. They presently have a $23.50 price target on the stock, up from their prior price target of $21.00. UBS Group‘s price target suggests a potential upside of 1.12% from the company’s current price.

A number of other research firms have also recently commented on SGRY. TD Cowen reiterated a “buy” rating and issued a $19.00 target price on shares of Surgery Partners in a research note on Friday, September 18th. Royal Bank Of Canada cut shares of Surgery Partners from a “moderate buy” rating to a “hold” rating and set a $23.50 price target for the company. in a report on Monday. Benchmark reissued a “buy” rating on shares of Surgery Partners in a report on Tuesday, August 11th. Weiss Ratings raised shares of Surgery Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Finally, Stonex Financia downgraded Surgery Partners from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.14.

Read Our Latest Research Report on SGRY

Surgery Partners Stock Performance

Shares of SGRY stock opened at $23.24 on Wednesday. The business’s fifty day simple moving average is $14.75 and its 200-day simple moving average is $14.57. The company has a market cap of $3.04 billion, a PE ratio of -33.20, a PEG ratio of 4.87 and a beta of 1.90. The company has a current ratio of 1.95, a quick ratio of 1.78 and a debt-to-equity ratio of 1.18. Surgery Partners has a 12-month low of $11.41 and a 12-month high of $23.44.

Surgery Partners (NASDAQ:SGRY – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The firm had revenue of $848.90 million for the quarter, compared to the consensus estimate of $830.03 million. Surgery Partners had a positive return on equity of 0.88% and a negative net margin of 2.63%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 EPS. Analysts expect that Surgery Partners will post 0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Teresa DeLuca acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was bought at an average cost of $14.35 per share, with a total value of $143,500.00. Following the transaction, the director owned 66,843 shares of the company’s stock, valued at $959,197.05. The trade was a 17.59% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Surgery Partners

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new position in shares of Surgery Partners in the 2nd quarter valued at approximately $1,205,000. Whitefort Capital Management LP acquired a new stake in shares of Surgery Partners during the second quarter worth about $15,142,378. Corient Private Wealth LP acquired a new position in shares of Surgery Partners during the second quarter worth $1,211,000. Penn Capital Management Company LLC purchased a new position in shares of Surgery Partners during the second quarter worth about $2,941,000. Finally, Hsbc Holdings PLC grew its stake in Surgery Partners by 54.5% during the second quarter. Hsbc Holdings PLC now owns 2,958,912 shares of the company’s stock worth $48,912,000 after buying an additional 1,043,244 shares during the period.

About Surgery Partners

(Get Free Report)

Surgery Partners, Inc is a U.S.-based healthcare services company that operates and manages ambulatory surgery centers and surgical hospitals. The company works with physicians, health systems and other healthcare providers to deliver outpatient surgical care in facilities designed for same-day procedures.

Its facilities provide surgical services across specialties such as orthopedics, pain management, ophthalmology, gastroenterology, urology, gynecology and general surgery. Surgery Partners also supports its operations with clinical, administrative and revenue-cycle services intended to help physicians and facility partners manage patient care and practice operations.

Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners has expanded its platform through acquisitions, joint ventures and other partnerships.

Featured Articles

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.